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extent of generic drug utilisation for the two main drug
schemes, the General Medical Services (GMS) scheme and
the Drugs Payment (DP) scheme, was measured. Under
the GMS scheme, all prescribed drugs are fully reim-
bursement by the state. Under the DP scheme the pa-
tient pays up to €70/month for prescribed drugs and the
state pays the remainder. Potential savings from generic
substitution for both schemes were investigated.
METHODS: The cost and quantity of drugs dispensed in
2001 were analysed using a national primary care pre-
scribing database, which contains information on the
brand name, strength, form and cost of prescribed drugs.
Drugs are categorised into 4 classes on the database:
generic, branded generic, proprietary drug with a generic
equivalent, proprietary drug with no generic equivalent.
The analysis was performed using JMP and SAS (SAS
Institute Inc.). RESULTS: On the GMS scheme 22% of
prescription items were dispensed generically, whereas on
the DP scheme 12% were dispensed generically. On both
the GMS and DP schemes 18% of prescription items were
dispensed as a proprietary preparation when a generic
equivalent was available. Substitution of the cheapest
generic equivalent preparation would result in estimated
annual savings of €14.54 million (3.4% of total expen-
diture) on the GMS scheme and €4.88 million (2.7% of
total expenditure) on the DP scheme. CONCLUSIONS:
The results highlight the potential cost savings, which
could be made by generic substitution, facilitating the
most efﬁcient use of the limited drugs budget.
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OBJECTIVES: The objective of this study is to describe
the current state of Philippine drug prices across various
data sources. METHODS: Retail drug price data was
gathered for a list of the 124 pharmacologically active
ingredients most commonly reimbursed by PHIC. This
list was generated from a systematic sample of 410 claims
from a total 305,482 processed claims ﬁled at the
National Capital Region ofﬁce during the calendar year
2000. This sample also served as a source of national
drug price data. Other sources of price data included a
survey of international drug prices, and a joint Depart-
ment of Health-Management Sciences for Health drug
price survey from 64 points of sale throughout the
country. RESULTS: Data gathered from local sources 
displayed a large degree of variation. From the PHIC
processed claims sample, the average relative price dif-
ference between identical drug preparations was 382.7%
(SD ± 1080.3). Similarly, price data from the joint DOH-
MSH survey displayed an average relative price difference
of 247.4% (SD ± 538.4). Comparison of local to inter-
national price data showed that Philippine prices for
certain drug products may be 10–15 times higher than
those if purchased outside of the country. CONCLU-
SIONS: The results of this study substantiate the common
belief that there is extreme variation and inﬂation of drug
prices in the Philippines. Other related studies have also
shown that these considerable discrepancies cannot be
attributed wholly to the more common reasons for 
price variance such as transportation, purchasing power,
market ﬂuctuations, etc. This study’s ﬁndings also give
PHIC further license to develop an index of drug refer-
ence prices that will serve as a basis for drug reimburse-
ment in the hope of encouraging the more rational and
fair pricing of drugs.
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OBJECTIVES: To determine ﬁnancial and professional
beneﬁts to examinees for Board of Pharmceutical Spe-
cialties (BPS) certiﬁcation. METHODS: An anonymous
web-based survey was developed and pre-tested. The
survey was sent to all 84 US colleges of pharmacy. Demo-
graphics captured included college size, mean yearly
research dollars, faculty size, and enrollment. Information
regarding numbers of BPS-certiﬁed faculty, the extent to
which BPS certiﬁcation was considered in recruitment,
and compensation/incentives provided to faculty for cer-
tiﬁcation was obtained. RESULTS: Thirty-ﬁve surveys
were returned. Deans completed surveys (54%) and divi-
sion/ department chairs (43%). Mean number of full-time
faculty members/institution was 24 (range 9–60). Mean
number of full-time board certiﬁed faculty members was
7 (20%), with a range of 0–25. No institution required
board certiﬁcation for new faculty members; 8 (23%)
anticipated such a requirement for currently non-certiﬁed
faculty. Costs to examinees are estimated with minimum
and maximum expenses varied for test cases. The survey
revealed that expenses reimbursed varied considerably,
with 34% reimbursing no expenses, 34% reimbursing a
preparatory course and examination fee, 23% reimburs-
ing the examination fee only if the examinee is success-
ful, and 11% reimbursing travel expenses. The amount
of reimbursement was tabulated. While 66% of respon-
dents stated they encouraged faculty to seek board certi-
ﬁcation, fewer had faculty incentives. Only 17% provided
salary increases and 6% granted promotion to recognize
faculty members. Most institutions considered board cer-
tiﬁcation in promotion and tenure (66%) and provided
public recognition of successful examinees (51%). Poten-
tial values were attached to the promotion and tenure and
public recognition variables based on literature values.
CONCLUSIONS: BPS certiﬁcation is not required at this
